Evommune to present Phase 2a EVO301 atopic dermatitis data at EADV 2026

Evommune, Inc. (NYSE: EVMN) said on September 23, 2026 that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis will be presented in a late-breaking oral session at the European Academy of Dermatology & Venereology Congress in Vienna, Austria, running September 30 through October 3, 2026.¹

EVO301 is described as a long-acting, native IL-18 binding protein fused to a serum albumin binding Fab, designed to neutralize aberrantly upregulated IL-18 activity.¹ The company said IL-18 acts upstream of the Th2 pathway and also influences Th1, Th17/22, and innate immune signaling.¹

CEO Luis Peña said an estimated 29 million patients still need advanced therapy for moderate-to-severe atopic dermatitis, and that IL-18 inhibition has shown clinical effects on Th2-driven disease consistent with current treatment approaches, while also offering a broader upstream mechanism intended to address multiple inflammatory pathways in this heterogeneous condition.¹ He added that the company is building on topline results reported earlier in 2026, with a Phase 2b dose-ranging study of EVO301 in moderate-to-severe atopic dermatitis expected to begin in mid-2027.¹

The presentation is titled "Positive Top-line Data from the Phase 2a Proof-of-Concept Trial of EVO301, a Novel IL‑18 Binding Protein, in Patients with Moderate-to-Severe Atopic Dermatitis," and is scheduled for Thursday, October 1, from 4:30 to 4:45 pm CEST (10:30 to 10:45 am EDT) in Hall A¹, presented by a dermatology faculty member at the Icahn School of Medicine at Mount Sinai.

The filing noted forward-looking statement risks are detailed in Evommune's annual report filed with the SEC in March 2026, updated by a quarterly filing in August 2026, and in other future SEC filings.